Funding for this research was provided by:
United Therapeutics Corporation
Received: 22 September 2020
Accepted: 28 April 2021
First Online: 24 August 2021
: This study was conducted in accordance with the amended Declaration of Helsinki. One of RTI International’s three institutional review boards approved the protocol and all study materials (STUDY00020846), and informed consent was obtained from all study participants.
: Not applicable.
: PC, ACN, and HC are employees and shareholders of United Therapeutics. RC, RM, and LD are employees of RTI Health Solutions. KBH has received grants/contracts, does consulting, and/or is on the speaker’s bureau of Actelion Pharmaceuticals, Bayer Healthcare, Eiger Pharmaceuticals, Gilead Sciences, Gossamer Bio, Reata Pharmaceuticals, and United Therapeutics. SCM has consulted for Actelion Pharmaceuticals, Liquidia, and United Therapeutics. HMD has consulted for Actelion Pharmaceuticals. This study was funded by United Therapeutics Corporation.